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ABSTRACT 
Degree Project, Programme in Medicine 2017. Author: Sofia Henriksson. Institution: 
Pharmacology, Pharmacy & Anaesthesiology Unit, University of Western Australia, Perth. 
Title: “What is the correlation between saliva levels of dexamphetamine and performance 
on visual and auditory-visual illusions?”  
Background: Schizophrenia is a psychiatric disorder associated with dopamine (DA) 
hyperactivity. Given that dexamphetamine (DEX) elevates levels of DA in the brain, DEX 
challenges can be used to model schizophrenia in research. Hallucinations and delusions are 
two characteristic symptoms of schizophrenia and psychosis. Previous research suggests a 
widened temporal binding window in which sensory stimuli can bind to form one perception 
as a mechanism of how DA gives rise to hallucinations and delusions. Using illusion tests, 
sensory stimuli can be manipulated and perception measured in an objective manner. Looking 
into temporal and spatial windows in the visual-visual and visual-auditory sensory modalities, 
26 healthy participants tested the Three Flash Illusion test (3-FI), Sound Induced Flash 
Illusion test (SIFI), Visually Induced Flash Illusion test (VIFI), Phantom Word Illusion (PWI) 
and McGurk effect on one day given DEX and one day given placebo. Aims: To determine 
levels of DEX in saliva samples taken during the testing days and correlate those levels 
closest in time to the illusion tests with performance on illusion test. Methods: Liquid-liquid 
extraction and high performance liquid chromatography was used to determine the levels of 
DEX in saliva. Raw data was analysed primarily with principal components analysis. Results: 
For those significant differences in performance on illusion tests between DEX and placebo 
days, levels of DEX in saliva correlated positively only with performance on VIFI and PWI 
tests and not in the McGurk illusion. Conclusions: DEX-levels in saliva showed in our study 
to be an unreliable predictor of performance on the illusion tests. However, more studies with 
greater sample sizes are necessary to draw any final conclusions.  
 
Key words: Dexamphetamine, saliva, temporal window, McGurk, phantom word, flash 
illusion 
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1. BACKGROUND 
1.1 Introduction to schizophrenia and the dopamine hypothesis 
Schizophrenia is a psychiatric disorder, according to the diagnostic criteria of the DSM-V, 
characterized by symptoms including delusions, hallucinations, disorganized speech, grossly 
disorganized or catatonic behaviour and negative symptoms (2). Negative symptoms are 
diminished emotional expression, avolition (inability to motivate oneself to meaningful 
activities), alogia (poverty to speak), asocial behaviour (reduced interest in social activities)  
and anhedonia (inability to feel pleasure from usually enjoyable activities) (2). Although the 
exact pathways to schizophrenia are not yet fully understood, the neurotransmitter DA has 
been shown to play a significant role in the pathogenesis of the disease (3). DA’s role in 
schizophrenia is formulated in the “dopamine hypothesis”, updated over the years. The 
dopamine hypothesis is reviewed in Howes (3) in which a revised dopamine hypothesis is 
presented, referred to as “version III”. According to this version, they state that multiple 
factors; a combination of genes and environmental influences, contribute to the development 
of dopamine dysregulation which in turn is the “common pathway to psychosis in 
schizophrenia”. The dopamine dysregulation manifests as elevated pre-synaptic striatal 
dopamine availability and striatal synaptic dopamine release. Howes argues also that because 
anti-psychotic drugs blocking dopamine is efficient treatment for any psychosis, regardless of 
original diagnosis, dopamine hyperactivity is associated with psychosis in general rather than 
schizophrenia alone. Hallucinations and delusions are major characteristics of psychosis. 
Hallucinations are perceptions of reality without actual present stimuli (2, 4), for example 
hearing voices when there are none(2). Delusions are fixed beliefs that persist by the sufferer 
even though conflicting evidence is present (2). Even though DA has been associated with 
these symptoms, the mechanisms to how DA gives rise to them is, however, still not fully 
understood. One suggested mechanism for both delusions and hallucinations is that out of 
context dopamine-firing causes addition of salience to irrelevant stimuli. Paying attention to 
irrelevant stimuli over time would further explain development of delusions and 
hallucinations (5). Another proposed theory is that dopamine leads to impaired integration of 
prior beliefs and current sensory information (6). Another suggested mechanism through 
which dopamine acts is widening of temporal and spatial windows for different sensory 
stimuli to bind (7). While proposed separately, it may well be that all three mechanisms occur 
and are inter-related. 
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1.2 The amphetamine model 
One problem studying individuals with schizophrenia is treatment with antipsychotics, a 
possibly confounding factor difficult to control for. To avoid this, recent research has been 
done on healthy individuals, given drugs that elevate DA levels in the brain (7, 8). Giving 
amphetamine in high doses will induce psychosis similar to that found in schizophrenia (9). 
Amphetamine challenges can thus be used as a model to investigate the role of dopamine in 
the pathogenesis of the disease and foremost psychosis. DEX is chemically similar to the 
neurotransmitters dopamine, noradrenalin and serotonin making it a competitive substrate to 
their reuptake transporters (DAT, NET and SERT) from the synapse back to the nerve 
terminal. Within the cell, DEX also prevents the transport of the neurotransmitters into their 
storage vesicles (through binding to VMAT2). The net result is a reversal of the direction of 
the catecholamine (and to a lesser extent, the serotonin) transporters, actively pumping 
monoamines out into the synaptic cleft, independent of the neuron electrical activity (10).  
 
1.3 Illusions and its importance in investigation of pathology in psychosis 
Illusions are, in contrast to hallucinations, misperceptions of stimuli that are present in the 
environment and occur in “normal” sensory processing (4). Illusion tests are thus a valuable 
method to investigate perception of sensory stimuli. Illusion tests have the potential to 
investigate whether individuals with schizophrenia and healthy individuals administered DEX 
differ in perceptions of sensory stimuli compared to healthy controls. If both individuals with 
schizophrenia and participants administered DEX differ from controls in their experiences of 
illusions in a similar manner, this indicates that it is likely that the patients’ experiences are 
due to the increase in DA release, and not due to the antipsychotic or other treatments or 
characteristics that they may have.  
Temporal window (as introduced previously) is one factor that can be manipulated in 
illusion tests. Previous research from this lab has particularly been interested in the idea of a 
widened temporal binding window as a possible mechanism of psychosis. This theory is 
based on observations from the study by Albrecht et al (2011) (7) on the rubber hand illusion. 
In the study, DEX increased participants’ ratings of a rubber hand as being their own when a 
paintbrush was stroked asynchronously on the rubber hand (in view) and participants’ own 
hand (out of view). In the placebo group, however, the illusion strength was weakened in the 
asynchronous condition. A widened temporal window as an effect of increased DA firing 
would allow for stimuli that otherwise would be excluded in perception processing, to 
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temporally be allowed into the processing. Using this as an explanation of the results, healthy 
controls would thus be able to tell that the touch from the paintbrush and the visual cue, 
temporally incoherent, come from two different sources. Individuals with DEX, on the other 
hand, with the suggested widened temporal window would allow the two temporally 
incoherent stimuli to be perceived as coming from one single source.  
 
1.4 Flash illusions 
Previous studies have shown that at a certain interstimulus interval, ISI, between two 
flashes, the two flashes can be perceived as three (11). Bowen (11) showed that this occurs at 
approximately ISI 100 ms in healthy participants. Norton (12) confirmed this finding, and 
found further that individuals with schizophrenia tend to get the illusion at longer ISI’s (130 
ms), proposing a widened temporal window for the integration of the visual stimuli. Shams 
(13) showed that auditory stimuli can also induce a phantom flash in healthy participants. The 
study showed that as only one target flash is shown, healthy participants perceive more than 
one flash when two auditory beeps are played in close proximity to the flash. Chatterjee (14) 
investigated a flash illusion phenomenon with spatially incongruent flashes in healthy 
participants. The study found that a single target flash in a target position can be perceived as 
more flashes if there are confusing peripheral flashes, spatially separated from the target flash. 
The more inducing flashes, the more phantom flashes perceived in the target location. The 
study also showed that the closer the inducer flash is to the target flash, the more likely it is 
for participants to perceive a phantom flash. This study thus investigated the spatial binding 
window.  
Suggesting that DA increases the temporal and spatial binding windows it could be 
expected to see greater illusion strength at greater ISI in individuals administered DEX and 
when the inducing flashes are further away from the target flash, compared to individuals 
administered placebo. A study by Jha (15) investigated individuals administered DEX and 
placebo in a cross-over design in similar flash illusion tests, and found the outer boundary of 
the temporal window to be around 200 ms, however the same for both DEX and placebo 
conditions. There were, on the other hand, insufficient ISIs near the peak effect, so it could 
not be determined if DEX shifted the peak to a longer ISI, as the temporal binding window 
hypothesis would suggest.  
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1.5 The McGurk effect 
The McGurk effect involves the audio-visual sensory modalities. It is a misperception of 
incongruent visual and auditory stimuli first described by McGurk and MacDonald in 1976 
(16). They found that syllables said by an actor cut together with a visual movie by the actor 
pronouncing an incongruent syllable may be perceived by healthy participants as a fusion 
between the two syllables, as the syllable heard or, to a lesser extent, the syllable seen. That 
is, if the actor articulated with the lips “ga”, but the audio-recording played “ba”, the 
responses could be either the lip reading “ga”, the heard “ba”, a chimeric of the two, “da”, or 
(for the visual-auditory combination ba-ga) a combination “bga”.  The relative frequencies of 
the different kinds of responses have been reported to be 77.9% (auditory), 18.9% (chimeric), 
2.2% (visual) and  1% (combination) (17). 
Individuals with schizophrenia who have had electroencephalograms while listening to 
repeated simple auditory stimuli (beeps) or watching repeated simple visual stimuli (light 
flashes) have been shown to have consistent reductions in amplitudes and peak latency of 
auditory P300, but not so consistent of visual P300, an average positive brain potential with 
an onset of approximately 300 ms after auditory stimulus onset, and assumed to be evoked by 
the stimulus, as an indicator of attention and working memory towards that stimulus (18). In 
the study of Albrecht (8), healthy volunteers given 0,45 mg/kg (PO) dexamphetamine showed 
reduction in amplitude of P300 after auditory stimuli, but no reduction in P300 after visual 
stimuli. This suggests that dopamine hyperactivity might lead to a decreased attention of 
auditory stimuli, letting visual cues have a greater influence on perception than auditory cues. 
Taking this theory in to the context of the McGurk illusion, it can be hypothesised that 
individuals would increase their responses of “seen” and "chimeric" (“fused”) syllables and 
reduce their responses of “heard” syllables after administration of DEX. 
 
1.6 Phantom word illusions 
The phantom word illusion engages the auditory-modality in which a word played on 
repeat makes the listener perceive, after a certain time of repetitions, words other than the one 
played on repeat. This illusion was originally developed from the Octave Illusion by Deutsch 
in 1974 (19) in which a high-pitch tone was played in one ear and a low-pitch tone in the 
other ear simultaneously, but alternating between right and left ear. Right handed people 
perceived in general only a low tone in the left ear and a high tone in the right ear. In an 
updated version of the illusion, in which the tones were replaced with the words “high” and 
“low”, an English speaking population reported hearing other words than “high” and “low”, 
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for example “buy-loan” and “long-time” (20). As introduced previously, one hypothesis of 
hallucinations in schizophrenia is that they are due to impaired attentional salience to the 
relevant cues and increased salience of irrelevant cues, leading to perceptions of objects that 
are not there (5). Applying this theory to the phantom word illusion in which novel words are 
heard that are not spoken, this could be explained as being misperceptions of the actual 
auditory stimuli present. We suggest that the primary cues the nervous system uses to 
determine relevance are the temporal and spatial coincidence, along with the stimulus 
properties that increase salience (e.g. intensity, novelty and past history of prediction of 
motivationally significant events). Arguing that DA increases the temporal window it is thus 
reasonable to expect that people treated with DEX will hear more words and hear them sooner 
(i.e. with a shorter latency) when there is an increase in the interstimulus interval between the 
sounds in the right and left ears. This prediction was, however, not validated in a pilot study 
of the phantom word illusion in people given 0,45 mg/kg DEX, PO, with only one ISI 
between the sounds in each ear (21). Expanding the study to test the illusion with different 
and greater ISI’s would thus allow for investigation of the limits of the temporal window, and 
whether there is a widened temporal window in individuals administered DEX compared to 
individuals administered placebo.  
1.7 Levels of dexamphetamine in saliva 
There are previous research on quantification of DEX in plasma (22) and how it correlates 
to subjective and physiological measures (23-25). How DEX concentrations in plasma 
correlates to performance on illusion tests has, however, to the author’s knowledge not been 
investigated. Rossini (26) worked out a method of how to detect and quantify DEX in saliva 
using reversed phase high performance liquid chromatography (HPLC) and correlate to 
performance on two illusion tests. Rossini worked out the method based on the study by 
Kristensen et al. (27) in which fluvoxamine was analysed in plasma and breast milk, also with 
HPLC. Levels of DEX in saliva as a predictor of performance on illusion tests is thus a 
relatively unexplored area. Further studies are needed to confirm the findings of Rossini; how 
levels of DEX in saliva varies also with physiological and psychological measures. 
 
2. AIMS 
In the studies of Hourani (1) and Lloyd (28), different versions of the flash,- Phantom 
word-, and McGurk illusion tests described previously (12-14, 16, 20) were tested on healthy 
participants; one day they were administered placebo and one day DEX. Their aims were to 
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investigate the effect of DEX on strength of illusions and differences in temporal- and spatial 
windows. Details of the individual illusion tests are described in the methods-section. The 
setup of this study was firstly to determine levels of DEX in consequtive saliva samples taken 
during the days of testing. By using the data from the illusion tests with significant differences 
in illusion scores between DEX and placebo days, this study aimed further to determine: 
• The day-course concentrations of DEX in saliva. 
• The correlation between: 
o DEX-levels in saliva and physiological measures. 
o DEX-levels in saliva and performance on illusion tests. 
o Rate of change of DEX-levels in saliva and performance on illusion tests. 
 
3. ETHICAL CONSIDERATIONS 
The study of Hourani (1) and Lloyd (28) was approved by the Human Ethics Office of 
Research Enterprise, approval # RA/4/1/7557. This author’s contribution with analysing 
DEX-levels in saliva was done with de-identified saliva samples.   
 
4. METHODS 
4.1 General methods 
The general procedures of this study was developed, and carried out, by Hourani (1) and 
Lloyd (28). 26 participants (14 women, 12 men) were recruited to the study through word-by-
mouth, posters in the pharmacological building at the University of Western Australia and 
promotion on lectures held by Prof Mathew Martin-Iverson. Participants were aged 18-59 
years with a mean weight of 71 kg (SD 12 kg). All participants provided written, informed 
consent and had a physical and psychiatric evaluation by a psychiatrist previous to the 
experiments to determine eligibility to participate. They were not economically compensated, 
but offered lunch on both testing days. Exclusion criteria were ages >59 and <18 (22.38 
±4.47) years, previous psychiatric, neurologic or cardiovascular disorders and regular 
prescribed medication. For a more detailed list, see appendix 1. On the day of testing 
participants were asked not to have taken any drugs within 24 hours, including prescription 
medications (except oral contraceptives and acne medication), coffee and nicotine. This was a 
double-blind, placebo -controlled, balanced, crossover study. Participants were pseudo-
randomized to an identification number and to their first treatment, placebo or DEX, having 
the one not previously taken on the next session with at least 7 days apart. Participants were 
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given 0.45 mg/kg of DEX, mean dose 31.6 mg (SD 5.75 mg) of capsules with 
dexamphetamine-sulphate or placebo, placebo capsules were of the same number and of 
identical appearance but contained glucose. The clinical dose for treatment of Attention 
Deficit Hyperactivity Disorder (ADHD) for an adult ranges between 20-70 mg/24 hours (29).  
Triplicate measurements of blood pressure and heart rate and duplicate measurements of 
body temperature were taken prior to ("0 min"), and at 80, 120, 210 and 270 minutes after 
administration of treatment. The physical measurements were done by the same investigator 
(not carrying out the illusion-tests because of the parameters giving away the condition). 
Saliva samples were collected 5 times prior to treatment and at 70, 130, 180 and 225 minutes 
post treatment. For detailed, summarised schedule from testing day, see appendix 2. 
Participants were offered a strawberry-flavoured gum (previously shown not to change saliva 
pH (30)) to chew and throw away 3 minutes prior to saliva collection, if their mouth was dry. 
Participants were asked to spit at least 1 ml per sample. Saliva-samples were stored in a 
freezer kept at -80°C. 
Before administrating drug or placebo, participants filled in the Amphetamine Mood 
Questionnaire (AMQ) to assess subjective amphetamine effects as a baseline. The AMQ was 
also completed another four times during the day post-treatment approximately at the same 
times as saliva-collection. Three different psychiatric scales were also used to assess 
psychosis-proneness during the testing days; the Brief Psychiatric Rating Scale (BPRS) 
assessed at 90 minutes’ post treatment (previously shown to be the peak of subjective 
experiences (15)), the Scale for the Assessment of Positive Symptoms (SAPS) and Magical 
Ideation Scale (MIS). The BPRS and SAPS were assessed by the same examiner in all trials.    
4.2 Illusion tests 
Flash illusion tests 
Three different flash illusion tests were used by Hourani (1). Common for all three was 
that participants were instructed to focus on a cross on a screen and told that a number of 1, 2, 
3 or more flashes would appear in the sample place as the cross had been after pressing any 
key (target position). In a Three Flash Illusion test (3-FI), similar to that of Norton (12), the 
temporal window was investigated. Two spatially coincident flashes were displayed at 
different interstimulus intervals after each other, participants asked to count the number of 
flashes perceived. The independent variable was time between the two flashes, also called 
interstimulus interval (ISI) and the dependent variable was number of perceived flashes, three 
being the illusion (see figure 1). In a Sound Induced Flash Illusion (SIFI), similar to that of 
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Shams (13), two auditory beeps were played after a single target flash. Again, the independent 
variable was the ISI, here time between the two beeps, and the dependent variable number of 
flashes perceived, investigating temporal window in audio-vision (see figure 2). In a Visually 
Induced Flash Illusion (VIFI), similar to that of Chatterjee (14), both spatial and temporal 
windows in vision were investigated. Two irrelevant, “inducing”, flashes, spatially non-
coincident from a target flash were displayed. There were two independent variables: 
• Position of the inducing flashes to investigate the spatial window. Positions 
varied between 3, 6, 9 and 12° eccentricities from target- to inducer flash. 
• Time between inducer flashes, ISI, investigating the temporal window. ISI’s 
varied between 25, 42, 50, 75 and 100 ms.  
See figure 3 for illustration. 
 
 
 
  
Figure 1: Illustration of events on screen in the three flash illusion test (3-FI) in study by Hourani (1). + = focus point, 
T= target flash, ISI = interstimulus interval. 
Figure 3: Illustration of events on screen in visually induced flash illusion (VIFI) in study by Hourani (1). + = 
focus point and target position, T = target flash, I = irrelevant flash, ISI = Interstimulus interval, X° = distance 
between target and irrelevant flash. 
Figure 2: Illustration of events on screen in sound induced flash illusion (SIFI) test in study by Hourani (1). + = 
focus point, T= target flash, speaker = sound, ISI = Interstimulus interval. 
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The phantom word illusion 
Lloyd (28) used a version of the phantom word illusion test, similar to that of Deutsch (20). 
Participants were wearing headphones with an auditory tape playing a two-syllable word on 
repeat. Two different words were used in separate trials being “harvey” and “highlow”. The 
word was first played in one ear, followed by the same word being played in the next ear, 
repeating over and over again. The time between the play in the different ears was 
manipulated with 5 different interstimulus intervals, ISI’s, of 220, 440, 660, 880, 1 100 ms. 
For example, for ISI 220 “highlow” was played in the right ear, followed by silence for 220 
ms before “highlow” playing in the left ear, followed by another silence of 220 ms before 
again playing “highlow” in the right ear. The “harvey”-track was always in the first trial of 
each new ISI, followed by the “highlow” track with the same ISI-condition, moving from the 
lowest ISI to the highest. Instructions to participants were to press a button on a joystick when 
they heard a new word other than the original word, and say it out loud. The independent 
variable was the interstimulus interval (ISI). The dependent variables were how many new 
words that were perceived other than “harvey” or “highlow” (count) and the time from start of 
trial to the perception of the first new word (latency).   
 
The McGurk illusion 
Lloyd (28) used a version of the McGurk illusion similar to that of 
McGurk (16) with both a female and a male actor, manipulating also the time 
between visual stimuli to auditory stimuli (asynchronous conditions), in order 
to investigate the temporal window in visual-auditory modalities. Videotapes 
of an actor’s face articulating syllables was cut with different auditory 
stimuli; the same as, or different to, the syllable actually being articulated. 
The 8 different syllable combinations can be found in table 1. The room was 
dimly lit and participants had headphones on. Each of the different conditions 
included a synchronous- (ISI = 0) pair and asynchronous pairs with ISI’s of 
400, 500, 600, 700, 800, 900 and 1000 ms. Participants watched each tape 
three times. The dependent variables 
were syllable perceived, the 
confidence of the perception and 
differences depending on sex of 
actor. See figure 4 for illustration. 
 Table 1: Visual and audio 
stimuli in the McGurk 
illusion. Control-
conditions in italic. 
Visual Audio 
ba ba 
fa fa 
ba fa 
ga ba 
ba ga 
pa ka 
fa ba 
ka pa 
Figure 4: Illustration of events on screen in the McGurk illusion test with examples 
of the different possible responses: the articulated, the seen or a chimer of the two 
syllables. ISI = Interstimulus interval. 
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4.3 Liquid-liquid extraction and reversed phase High Performance Liquid 
Chromatography (HPLC) 
To analyse levels of DEX in saliva, liquid-liquid extraction and reversed phase high 
performance liquid chromatography (HPLC) was used based on methods from Rossini (26) 
with modifications especially regarding the HPLC-method.  
 
Liquid-liquid extraction 
Saliva samples of approximately 1 ml were injected with a known, set, concentration of an 
internal standard: 3,4-Methylenedioxymethamphetamine (MDMA). Adding NaOH to the 
sample deprotonated DEX, making it more soluble in organic solvents. Extraction was first 
done in hexane/1%isoamyl alcohol and then back titration with hydrochloric acid was carried 
out, concentrating the drugs to a volume of 150 µl, ready to be used in the HPLC-
autosampler, a volume seen in Rossini (26) to give peaks of enough size for detection and 
integration. For detailed extraction-protocol, see appendix 3. 
 
HPLC 
In contrast to the work of Rossini (26), this study used a Waters 717 plus autosampler, 
Waters 1525 binary HPLC pump and waters 2487 dual l absorbance detector. The instrument 
method settings were, however, the same as used by Rossini (26): The mobile phase was a 
combination of 90% phosphate buffer and 10% acetonitrile, and a gradient analysis was used 
changing acetonitrile from 10% to 55% in 10 minutes with a flow of 0.5 ml/min. Gradient 
analysis was used in order to be able to get enough separation of DEX and MDMA peaks in 
the chromatogram. A complete run in the HPLC-machine took 18 minutes. The column was 
also the same: Phenomenex Gemini NX: 150 mm x 4.6 mm with 5 µm particle size and guard 
column 10x2.1 mm 5µm Hypersil BDS C18. Detection wavelength was set to 216 nm. 
Integration of peaks of DEX and MDMA was done with Empowerâ software.  
 
Identification method 
To be able to identify the peaks of DEX and MDMA, standards of different DEX 
concentrations and same MDMA concentration in phosphate buffer (see appendix 4) were 
run. Firstly, we identified the two peaks as either DEX and MDMA based on their relative 
areas to each other. Next, by running standards of DEX and MDMA before each new HPLC 
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session of participants’ samples, retention times of DEX and MDMA could be identified and 
compared to the peaks in participants’ samples. 
 
4.4 Calibration curve 
To determine the absolute rather than relative DEX-concentrations in saliva from 
participants, a calibration curve was necessary. This was done by using saliva samples from 
healthy volunteers (not taking medication). When running them through the extraction 
process, in addition to the set concentration of internal standard of MDMA, they were 
"spiked" with different concentrations of DEX. Because of difficulties measuring volumes of 
saliva, saliva samples of approximately 1 ml were pre-weighed before being spiked and going 
through extraction giving the concentrations of DEX and MDMA in saliva in units of ng/g. 
The different concentrations of DEX were prepared through dissolving 10 mg of solid DEX in 
100 ml of phosphate buffer, creating a stock solution (c=100 000 ng/ml). From the stock 
solution DEX concentrations of 10 000, 5 000, 2 500, 1 250, 625, 400 and 200 ng/ml were 
prepared. The MDMA solution was prepared from 10 mg of solid MDMA and dissolved in 
100 ml of phosphate buffer creating a stock solution (c=100 000 ng/ml). 3 ml of the stock 
solution was then added to 100 ml of phosphate buffer (c= 3000 ng/ml). Volumes of the 
different DEX concentrations and MDMA (c=3000ng/ml) to saliva were 100µl. Each of the 7 
different concentrations of DEX with the set concentration of MDMA were run through the 
extraction process twice a day (once in the morning, once in the afternoon) two days in a row. 
This was done to account for inter- and intra-day variability. Samples were stored in 
Eppendorf-tubes in a freezer at -80°C before being run through HPLC. When run in the 
HPLC, samples of 100 µl were injected in to 700 µL Waters polypropylene snap neck total 
recovery vials and the autosampler was set to two injections (duplicates) of 30 µl volumes 
each. Average ratios from the different DEX-concentrations (giving an average from 8 values 
for each concentration) were calculated. The final calibration curve was established by 
plotting the average ratios of DEX/MDMA vs the respective concentration of DEX (ng/g 
saliva).  
 
4.5 Determination of DEX-levels in saliva from participants 
Saliva samples from DEX-days went through the extraction protocol and HPLC procedure 
as described above. Duplicates were run for each sample. The peaks of DEX and MDMA 
were identified and integrated. Ratios of DEX/MDMA areas were calculated. Because of 
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duplicate runs, an average ratio based on two values for each saliva sample were calculated. 
The absolute DEX concentration was calculated with the equation of best line of fit from the 
calibration curve.  
 
4.6 Statistical Analyses 
Statistical analyses were carried out with R statistics using RStudio Graphical User 
Interface.  
 
Principal Components Analysis (PCA) 
For most of our data analysis we used principal components analysis (PCA). PCA can only 
use one value from each variable, a requirement met by subtracting values from DEX days 
from values from placebo days. The PCA transforms all data to a common scale and then 
looks for independent sources of covariation. It constructs a number of components that are 
orthogonal (statistically independent) in which the variables in a component co-vary, called 
“loadings” on the component. Variables in a component co-vary positively or inversely to 
each other. Variables with loadings of the same sign (positive or negative) have a positive 
correlation. A component can be thought of as a subpopulation within the population that 
share the same covariation of variables loaded onto the component. The number of 
components depend on the number of variables used in the analysis; the more variables the 
more components. Component 1 accounts for the greatest variance of the independent 
components, and the variance falls with the number of components in the same order. Cut-off 
for significant covariation was set to 0.3 in our study. 
 
Day-course variations of DEX 
To see the variation of DEX-levels in saliva over testing day, average values of DEX-
concentrations were calculated from all participants and plotted against the time of saliva-
collection (as minutes post treatment). This was done with RStudio .99.903 with the packages 
plyr 1.84, dply 0.50, methods 3.31, stats 3.31, graphics 3.31, and Rstatistics package 3.31, all 
for Mac OS 10.10.5. 
 
Physiological measures 
DEX-concentrations form saliva sample 3 (taken 130 min post treatment), systolic- and 
diastolic blood pressure and heart rate (taken 120 min post treatment) were analysed with 
PCA.  
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Visually induced flash illusion, VIFI 
The results from the study of Hourani (1) showed significant differences in performance on 
illusion tests between placebo and DEX in the 3-FI or SIFI. In the VIFI there were significant 
difference in number of perceived flashes between placebo and DEX days at position 6° (all 
ISI’s), and a significant difference between placebo and DEX at ISI 50 ms (all positions). We 
used PCA to analyse the variables: Difference in individual scores (DEX minus placebo) from 
only these conditions, DEX-concentrations from the 3rd saliva sample (closest in time to the 
illusion), difference in scores on AMP and AMW and the sum of the difference (DEX minus 
placebo) in scores of BPRS, MIS and SAPS (abbreviated psychosis). The same variables 
except changing DEX-levels in saliva with rate of change of DEX in saliva were also 
analysed with PCA. The rate of change of DEX in saliva was calculated as the individual peak 
DEX-level divided by the exact time of when that saliva-sample had been collected. 
 
McGurk illusion 
In Lloyd (28) there was no overall (male- and female actors) significant difference between 
DEX- and placebo treatment in proportions of audio-, visual- or chimer (of the two) syllables 
perceived, although there was a trend towards more chimeric and visual responses. On closer 
examination of the female actor recordings, listening to the sound in the absence of the video, 
it appeared that she either failed to produce a consonant sound on some words, or else they 
were so quiet as to not be picked up. We therefore re-analysed the data, using only the data 
from the male actor using a kernel density permutation test with 1000 permutations 
(Rstatistics packages sm 2.2-5.4 and boot 1.3-18).  
 The present study also sought to investigate the effect of DEX saliva levels obtained at 
225 min post-treatment (the time closest to the McGurk effect test) and the differences of the 
average scores from the asynchronous ISIs of 800, 900 and 1000 ms from the DEX treatment 
day minus those from the placebo treatment day.  
 
Phantom word illusion 
Lloyd (28) showed that for both count (number of words perceived other than highlow or 
harvey) and latency (time to the first new word perceived) the differences were greatest with 
highlow and greater ISI’s. Therefore, scores only from highlow and ISI greater than 440 ms 
were used in the present study. The DEX-levels were from the 2nd saliva sample, collected 
approximately 70 minutes’ post treatment, the phantom word-illusion being 75 minutes’ post 
treatment. The scores on the illusion test from placebo days were subtracted from scores from 
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DEX days. The psychological scores from AMQ, BPRS, MIS and SAPS were treated the 
same way as in analysis of VIFI. PCA was used to investigate dose-relationships between 
DEX-levels in saliva and scores on illusion and psychological scales. 
 
5. RESULTS 
5.1 Standard samples 
Running samples of the different DEX-concentrations (in buffer) in the HPLC gave two, 
well-defined peaks in the chromatograms. DEX was identified to be the peak of shortest 
retention time supported by the change in ratio of the areas of the two peaks looking at 
different concentrations of DEX and constant concentrations of MDMA. Figures 5 and 6 
provide two examples of the chromatograms with standards of DEX concentration 200 ng/ml 
and MDMA concentration 3000 ng/ml (figure 5) and DEX concentration 5000 ng/ml and 
MDMA concentration 3000 ng/ml (figure 6).  
  
Figure 5: Chromatogram from high performance liquid chromatography (detection wavelength 216 nm) with DEX concentration 
200 ng/ml and MDMA concentration 3000 ng/ml. Numbers on top of peaks indicates the time of detection. AU=absorbance unit. 
Figure 6: Chromatogram from high performance liquid chromatography (detection wavelength 216 nm) with DEX concentration of 
5000 ng/m and MDMA concentration 3000 ng/ml. Numbers on top of peaks indicates the time of detection. AU=absorbance unit. 
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5.2 Calibration curve 
Some samples were incorrectly handled during the extraction process: Samples with DEX 
concentrations 1250 ng/ml (2 values) and 2500 ng/ml (2 values) from day 2 and were 
excluded from analysis. Some samples gave inconclusive chromatograms due to failure of the 
HPLC-machine, making peaks impossible to integrate: Samples with DEX concentrations 
2500 ng/ml (day 1, afternoon sample 2), 10000 ng/ml (day 2, morning sample 2) and 1250 
ng/ml (day 2, afternoon sample 2) were also excluded. This resulted in a mean based on 5 
values for 2500 and 1250, and 7 values for 10000. All other DEX concentrations were 
calculated means from 8 values. All different DEX/MDMA-ratios for each DEX-
concentration were plotted in a graph with best line of fit. Thus calibration curve is shown in 
figure 7. The best line of fit has the equation: y=0.005x+0.1654.  
Figure 7: Calibration curve plotting mean ratios of DEX/MDMA vs concentration of DEX and a best line of fit with the 
equation y=0.005x+0.1654 and R2=0.99744. 
y = 0,005x + 0,1654
R² = 0,99744
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5.3 Variations in DEX concentrations and responses on AMP over day 
Data from saliva samples from participant 522 and 519 had to be removed due to failure of 
the HPLC-machine and inability to read chromatograms giving n=24 for analysis. Mean 
concentrations of DEX in saliva were plotted with mean scores on the euphoric subscale of 
AMQ (AMP) (figure 8) and mean difference in scores on the anxiety subscale of AMQ 
(AMW) (figure 9) over day.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8: Mean concentrations of DEX (±SEM) in saliva (left y-axis, black line) and mean scores on AMP-subscale 
(±SEM) (right y-axis, red line) vs approximate time post treatment. AMP=the euphoric subscale of the amphetamine 
mood questionnaire. Note that right y-axis starts at 40. Lines are drawn through the points. n=24. 
Figure 9: Mean concentrations of DEX (±SEM)  in saliva (left y-axis, black line) and mean difference in score (score 
from DEX day minus score from placebo day) on AMW-subscale (±SEM) (right y-axis, blue line) vs approximate 
time post treatment. AMW = the anxiety subscale of the amphetamine mood questionnaire. Lines are drawn through 
the points. n=24. 
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5.4 Physiological measures 
Lloyd (28) showed no significant main effect of temperature between placebo and DEX 
days why we decided not to include temperature in our analyses. Again, values from 522 and 
519 were excluded giving n=24. PCA of heart rate, diastolic- and systolic blood pressure and 
concentration of DEX in saliva with cutoff 0.3 gave 4 components with loadings presented in 
table 2. Importance of components are presented in table 3. Figure 10 shows the PCA plot of 
components 1 and 2. DEX-level in saliva has a positive relationship with diastolic and systolic 
blood pressure in component 1 accounting for 37% of the variance. DEX-level in saliva has a 
positive relationship with heart rate and an inverse relationship with systolic blood pressure in 
component 2 accounting for 28% of the variance. 
	
	
 
	
	
	
	
 
  	   
 Table 2: Loadings in principal components analysis with variables dias, sys, hr and Conc. Cut-off 
0.3. Values from variables were taken approximately 130 min post treatment. n=24.   
 Comp. 1 Comp. 2 Comp. 3 Comp. 4 
Dias -0.661  0.307 0.634 
Sys -0.670 0.304  -0.656 
Hr  -0.819 0.393 -0.401 
Conc -0.315 -0.412 -0.851  
Dias=Diastolic blood pressure, sys=systolic blood pressure, Hr=heart rate, 
Conc=concentration of DEX in saliva. 
Table 3: Importance of components in principal components analysis of the variables dias, sys, hr and Conc (loadings 
can be seen in table 2). Values of the variables were taken approximately 130 min post treatment. Values in the table 
have been rounded off to three decimal places. n=24. 
 Comp. 1 Comp. 2 Comp. 3 Comp. 4 
Standard deviation 1.219 1.067 0.952 0.686 
Proportion of Variance 0.371 0.284 0.227 0.118 
Cumulative proportion 0.371 0.656 0.882 1.000 
Figure 10: Principal components analysis of physiological measures (hr=heart rate, dias=diastolic blood pressure, sys=systolic 
blood pressure) and concentration of DEX in saliva (Conc) approximately 130 min post treatment. n=24. DEX-level has a positive 
relationship with dias and sys in Comp.1 accounting for 37% of the variance. DEX-level has a positive relationship with hr and an 
inverse relationship with sys in Comp.2 accounting for 28% of the variance. Cut-off set to 0.3. 
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5.5 Visually induced flash illusion, VIFI 
Again, values from 522 and 519 were excluded (n=24). PCA of AMW, psychosis (sum of 
difference in scores of SAPS, BPRS and MIS), AMP, difference in response on VIFI 
(response) and concentration of DEX (Conc) with cutoff 0.3 gave 5 components loadings 
presented in table 4. Importance of components are presented in table 5. Figure 11 shows the 
PCA plot of components 1 and 2. DEX-levels in saliva have a positive relationship with 
psychosis and response and an inverse relationship with AMP in component 1 accounting for 
32% of the variance. DEX-levels in saliva have a positive relationship with AMP, and an 
inverse relationship with response in component 2 accounting for 26% of the variance. 
	
	
	
	
	
	
 
 
 
Table 4: Loadings in principal components analysis with the variables amw, psychosis, amp, response and Conc. Values 
of all variables were values from DEX-day subtracted from placebo day. Values from the psychological measures were 
taken approximately 130 min post treatment. VIFI was 115 min post treatment. Cut-off 0.3. n=24.     
Table 5: Importance of components in principal components analysis of the variables amw, psychosis, amp, response and 
Conc (loadings can be seen in table 4). Values of the variables were taken approximately 130 min post treatment. Values in 
the table have been rounded off to three decimal places. n=24. 
 
 Comp. 1 Comp. 2 Comp. 3 Comp. 4 Comp. 5 
amw  0.748   -0.596 
psychosis -0.383  0.648 -0.577  
amp 0.382  0.751 0.430  
Response -0.463 0.455  0.688 0.314 
Conc -0.647 -0.313   -0.689 
Amw = anxiety subscale of amphetamine mood questionnaire (AMQ), amp = euphoric subscale of AMQ. Psychosis = 
sum of scores on BPRS (brief psychiatric rating scale), SAPS (subjective assessment of positive symptoms) and MIS 
(magical ideation scale) from DEX-day subtracted from placebo day. Response = score on VIFI (115 min post 
treatment), Conc=concentration of DEX in saliva from saliva sample taken 130 min post treatment.    
 Comp. 1 Comp. 2 Comp. 3 Comp. 4  Comp. 5 
Standard deviation 1.256 1.132 0.985 0.856 0.661 
Proportion of Variance 0.316 0.256 0.194 0.147 0.088 
Cumulative Proportion 0.316 0.572 0.766 0.912 1.000 
Figure 11: PCA of psychological measures (amp=positive subscale of AMQ, amw=anxiety subscale of AMQ and psychosis=sum of score 
from BPRS, MIS and SAPS), concentration of DEX (Conc) approximately 130 min post treatment and scores on VIFI-test (response) at 
position 6° and ISI 50ms only. n=24. DEX-levels have a positive relationship with psychosis and response and an inverse relationship 
with amp in Comp.1 accounting for 32% of the variance. DEX-levels have a positive relationship with amp, and an inverse relationship 
with response in Comp.2 accounting for 26% of the variance. Cut-off set to 0.3. n=24. 
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PCA of AMW, psychosis (sum of difference in scores of SAPS, BPRS and MIS), AMP, 
difference in response on VIFI (response) and rate of change of DEX in saliva (slope) with 
cutoff 0.3 gave 5 components with loadings presented in table 6. Importance of components 
are presented in table 7. Figure 12 shows the PCA plot of components 1 and 2. Response, 
slope and psychosis have a positive relationship in component 1 accounting for 33% of the 
variance. AMP and psychosis have a positive relationship and an inverse relationship with 
AMW in component 2 accounting for 20% of the variance. 
 
 
 
 
 
 
 
 
 
 
	
 
 
 
 
  
Table 6: Loadings in principal components analysis with the variables amw, amp, response, psychosis and slope. 
Values of variables were values from DEX-day sustracted from placebo day. Values from the psychological 
measures were taken approximately 130 min post treatment. VIFI was 115 min post treatment. Cut-off 0.3. n=24.     
 Comp. 1 Comp. 2 Comp. 3 Comp. 4 Comp. 5 
amw  0.531 -0.774   
amp  -0.627 -0.627 0.337  
response 0.524   0.836  
psychosis 0.507 -0.498   -0.669 
slope 0.567   -0.329 0.715 
amw = anxiety subscale of amphetamine mood questionnaire (AMQ), amp = euphoric subscale of AMQ. 
Psychosis = sum of scores on BPRS (brief psychiatric rating scale), SAPS (subjective assessment of positive 
symptoms) and MIS (magical ideation scale) from DEX-day subtracted from placebo day. Response = score on 
VIFI (115 min post treatment), slope = rate of change of DEX in saliva. 
 Comp. 1 Comp. 2 Comp. 3 Comp. 4 Comp. 5 
Standard Deviation 1.286 1.001 0.970 0.862 0.801 
Proportion of variance 0.331 0.204 0.188 0.149 0.128 
Cumulative Proportion 0.331 0.535 0.724 0.872 1.000 
Table 7: Importance of components in principal components analysis of the variables amw, amp, response, 
psychosis and slope (loadings can be seen in table 6). Values of the variables were taken approximately 130 
min post treatment. Values in the table have been rounded off to three decimal places. n=24. 
Figure 12: Principal components analysis of amp (positive subscale of AMQ), amw (anxiety subscale of AMQ), psychosis (sum of 
score from BPRS, MIS and SAPS), rate of change of DEX-level in saliva (slope) and scores on VIFI-test (response) at position 6° 
and ISI 50ms only. n=24. Response, slope and psychosis have a positive relationship in Comp.1 accounting for 33% of the 
variance. Amp and psychosis have a positive relationship and an inverse relationship with amw in Comp.2 accounting for 20% of 
the variance. Cut-off set to 0.3.  
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5.6 McGurk 
Due to technical problems (7 participants) and failure of the HPLC-machine and 
integrating peaks (2 participants), only data from 17 participants could be analysed. Figure 13 
shows a Kernel density comparison plot. It shows the distribution of auditory, chimeric and 
visual response-frequencies of DEX and placebo groups with male actor and ISI’s >400 ms. 
Lines within the blue shaded area indicates distributions that do not differ between placebo 
and DEX days 95% of the times (null hypothesis is true). Lines outside of the blue shaded 
area, however, indicates a difference in distribution of the different responses between DEX 
and placebo days 95% of the times. The kernel density estimation seen in figure 13 shows a 
significant main difference in distribution of responses between DEX and placebo days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCA of difference in scores of auditory responses (difa), difference in scores of chimeric 
responses (difc) and concentration of DEX in saliva with cutoff 0.3 gave 3 components with 
loadings presented in table 8. Importance of components are presented in table 9. Figure 14 
shows the PCA plot of components 1 and 2. DEX-concentration have a positive relationship 
with difa and an inverse relationship with difc in component 1 accounting for 68% of the 
variance. 
 
Figure 13: Kernel density comparison plot of McGurk scores from male actor and ISI’s >400 ms. The blue shaded area indicates 
the 95% confidence interval based on a bootstrap permutation test of equal distribution with 1000 samples. A permutation test 
indicates that the distribution of responses after DEX is significantly different from the distribution after placebo, p < 0.05, shifting 
responses from audio-dominated to chimeric responses, relative to placebo. n=17. 
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Table 8: Loadings in principal components analysis with the variables difa, difc and dex.sample5. Concentration 
of DEX approximately 225 min post treatment. McGurk 240 min post treatment. Cut-off 0.3. n=17.     
 Comp. 1 Comp. 2 Comp. 3 
difa 0.668 -0.219 -0.711 
difc -0.661 0.265 -0.702 
Dex.sample5 0.343 0.939  
Difa = difference in scores in auditory responses between DEX and placebo day (DEX minus placebo), difc = 
difference in scores in chimeric responses between DEX and placebo day (DEX minus placebo), dex.sample5 
= dex concentration in saliva sample 5, taken 225 minutes post treatment. 
Table 9: Importance of components in principal components analysis of the variables difa, difc and dex-
sample5 (loadings can be seen in table 8). Values in the table have been rounded off to three decimal 
places. n=17. 
 Comp. 1 Comp. 2 Comp. 3 
Standard Deviation 1.427 0.929 0.316 
Proportion of variance 0.680 0.288 0.033 
Cumulative Proportion 0.679 0.967 1.000 
Figure 14: Principal components analysis of difference in chimeric responses (difc), difference in auditory responses (difa) and 
DEX-concentration in saliva sample 5 (dex.sample5) closest in time to the illusion (approximately 225 min post treatment) (DEX 
minus placebo). DEX-concentration have a positive relationship with difa and an inverse relationship with difc in Comp. 1 
accounting for 68% of the variance. Cut-off set to 0.3. n=17. 
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5.7 Phantom word 
Due to failure of the HPLC-machine and setup difficulties in the first session days of the 
phantom word illusion, only 14 participants were included in the data analyses. PCA of 
concentration of DEX in saliva (Conc), sum of difference in scores of MIS, SAPS and BPRS 
(Psychosis), number of new words perceived (Count) and time to first new word (Latency) 
with cutoff 0.3 gave 4 components with loadings presented in table 10. Importance of 
components are presented in table 11. Figure 15 shows the PCA plot of components 1 and 2. 
Conc has a positive relationship with psychosis and latency, and an inverse relationship 
between count in component 1 accounting for 59% of the variance. Conc have a positive 
relationship with psychosis and count, and an inverse relationship with latency in component 
2 accounting for 21% of the variance.  
 
  
 
 
 
 
 
 
 
 
 
 
  
Table 10: Loadings in principal components analysis with the variables conc, psychosis, count and latency. 
Phantom word illusion test 75 min post treatment. Cut-off 0.3. n=14.     
 Comp. 1 Comp. 2 Comp. 3 Comp. 4 
Conc -0.438 0.590 -0.653  
Psychosis -0.452 0.507 0.716  
Count  0.552 0.424  0.688 
Latency -0.546 -0.464  0.683 
Conc = concentration of DEX in saliva sample 2 taken 70 min post treatment. Psychosis = sum of scores on 
BPRS (brief psychiatric rating scale), SAPS (subjective assessment of positive symptoms) and MIS (magical 
ideation scale) from DEX-day subtracted from placebo day. Count = Number of new words heard other than 
“highlow”. Latency = Time to first new word other than “highlow”.  
 Comp. 1 Comp. 2 Comp. 3 Comp. 4 
Standard Deviation 1.534 0.916 0.763 0.474 
Proportion of variance 0.589 0.210 0.145 0.056 
Cumulative Proportion 0.589 0.798 0.945 1.000 
Table 11: Importance of components in principal components analysis of the variables conc, psychosis, count and 
latency (loadings can be seen in table 10). Values in the table have been rounded off to three decimal places. n=14. 
Figure 15: Principal components analysis of concentration of DEX in saliva (Conc) (saliva sample 70 min post treatment, 
psychosis (sum of the difference score(DEX-placebo) from MIS, BPRS and SAPS), number of new words heard (count). Conc has 
a positive relationship with psychosis and latency, and an inverse relationship between count in Comp.1 accounting for 59% of 
the variance. Conc have a positive relationship with psychosis and count, and an inverse relationship with latency in Comp.2 
accounting for 21% of the variance. Cut-off 0.3. n = 14.  
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6. DISCUSSION 
6.1 Variations in DEX concentrations in saliva and responses on AMQ over day 
DEX-concentrations in saliva peaked on average in the 3rd saliva sample of the day, 
collected approximately 130 minutes post treatment. In the study of Rossini (26), this peak 
was found to be in the 4th saliva sample of the day, collected approximately 180 minutes post 
treatment. However, the error bars of the concentrations in the 3rd and 4th saliva samples in 
both this study and Rossini’s are, however, overlapping, suggesting consistent results. The 
mean scores of the AMP-subscale increased with DEX (compared to baseline), having the 
peak approximately 70 minutes’ post treatment. These findings are also consistent with 
previous studies showing that participants have an euphoric experience of DEX (23), and that 
this experiences is greatest 1-2 hours (23, 25, 31) after DEX-administration. Mean difference 
in scores (DEX minus placebo) of the AMW-subscale assessing withdrawal symptoms 
decreased slightly with DEX compared to baseline, and remained relatively constant 
throughout the test-day. In other words, anxiety was greater in patients on average on DEX-
days compared to placebo days, however, the greatest difference was found before DEX had 
been administered. These findings could be explained by the fact that participants are more 
nervous at the start of the day, and that a majority of participants get the euphoric rather than 
the anxious experience from DEX, making the mean difference in scores on AMW-subscale 
not change (if anything decrease) after DEX-administration.  
 
6.2 DEX-concentrations in saliva and physiological measures over day 
The results from the PCA shown in figure 10 shows that one subpopulation (component 1) 
of participants have DEX-concentrations in saliva that co-vary positively with systolic and 
diastolic blood pressure at approximately 130 min post treatment. This is reasonable, as all 
these parameters have their peaks around this time. Why heart rate is not loaded onto this 
component could be explained by the fact that heart rate have a slower rise and has not yet 
made its deflection. In Ashgar et al. (23) heart rate peaked at 500 minutes post treatment at 
which the study ended and the time of deflection was never reached. Another subpopulation 
(figure 10, component 2) of participants have DEX-concentrations that vary positively with 
heart rate and inversely with systolic blood preassure. This likely corresponds to the 
subpopulation discussed by Smith (24) as early responders to oral DEX who have an earlier 
peak for DEX levels and a greater, early rise in heart rate. Systolic pressure tends to drop 
before diastolic (32), so early responders may have decreasing systolic blood pressure at 130 
min while DEX-concentration and heart rate are still rising for this subpopulation.  
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Taken together, DEX-concentration had a positive relationship with blood preassure in and 
with heart rate, suggesting that dexamphetamine had a dose-response effect on measures of 
the sympathetic nervous system. 
 
6.3 Visually induced flash illusion, VIFI 
DEX-levels in saliva and illusion response loaded positively on to a component that 
accounted for the greatest variance in the data set (figure 11, component 1) indicating a 
possible dose-response relationship across individuals. Psychosis proneness also varied in the 
same direction in this component. In component 2, although accounting for less of the 
variance, anxiety scores co-varied in the same direction as response, and inversely with levels 
of DEX in saliva. That anxiety and DEX levels varies in opposite directions can be explained 
by the fact that most people get euphoric effects of DEX (thus, as DEX levels go up anxiety 
ratings go down). It is, however, difficult to explain why responses on illusion varies in the 
opposite direction as DEX concentration in this subpopulation as illusion strength was 
increased overall with DEX. For this subpopulation, DEX levels in saliva does not predict 
outcome on VIFI.  
Rate of change of DEX-levels in saliva also had a positive relationship with response and 
psychosis-proneness in one subpopulation (figure 12, component 1). Rate of change of DEX-
levels in saliva has previously shown to predict illusory response on another illusion-test 
(tactile funnelling) in the study by Rossini (26). In component 2 of the same PCA euphoric 
scores (AMP) logically co-varies positively with psychosis-proneness and inversely with 
scores on the anxiety subscale (AMW, assessing opposite measures).  
Taking the results from the study by Hourani (1) in the context of temporal and spatial 
windows, illusion-strength increased with DEX, but the highest responses occurred at same 
ISI as for placebo. This means that there is no widening of the temporal window, as opposed 
to our predictions or what Norton found in schizophrenia (12). This matches the finding of 
Jha (15) with a somewhat different VIFI procedure, where no effect of DEX was observed on 
either the maximal ISI at which the illusion occurred (~200 ms). The increase in illusion-
strength could be explained by attentional selectivity (salience of stimuli): The test included 
relevant and irrelevant stimuli leading to attention competition between the two different 
locations (attentional selectivity). Since DA has an effect on attentional selectivity, this acute 
increase in DA causes attention to irrelevant stimuli to increase, providing an explanation to 
the increase in illusion-strength with DEX. Regarding position (the spatial component) there 
was an increase in strength of illusion, the effect greatest at the 6 degree position. This may be 
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indicative of a widening of the spatial window, but cannot be concluded without a larger 
sample size and investigation of smaller changes in the spatial variable, to determine if there 
is a peak shift at lower distances. The spatial window has, to the author’s knowledge, not yet 
been investigated on individuals with schizophrenia and it is thus hard to compare the results. 
 
6.4 McGurk effect 
There was a difference in performance between DEX- and placebo days seen with the male 
actor at ISI >400 ms: the number of audio-dominated responses decreased and the number of 
chimeric responses increased significantly after DEX relative to placebo (figure 13). Looking 
at the actual DEX-levels in saliva samples from the time closest of the illusion there was, 
however, no correlation between level of DEX in saliva and degree of change in responses of 
audio-dominated and chimeric responses (figure 14, component 1). That is, no dose-response 
relationship across individuals could be seen. This may be due to any of the following 
reasons: (1) Insufficient power (i.e., sample size too small); (2) DEX effect is all-or-none 
effect; (3) Apparent DEX effect is due to an unknown confounding factor, although known 
confounding factors were counter-balanced; (4) DEX-levels near the time of illusion is not as 
reliable a predictor of illusion effects as the slope of the rise in levels; (5) insufficient 
variation in DEX levels as all people were given the same dose.  
Since the McGurk illusion test was carried out late in the day of testing (240 minutes’ post 
testing) we considered it useless to look into rate of change of DEX-levels in saliva as a 
predictor of illusory response. To the author’s knowledge, no previous studies have compared 
the levels of DEX in saliva with response on the McGurk illusion, which makes it yet harder 
to draw conclusions from the results.  
The McGurk illusion examines visual-auditory stimuli, which have previously been tested 
on individuals with schizophrenia with conflicting results: de Gelder (33), showed that 
individuals with schizophrenia reported more visually dominated responses than healthy 
controls, which is consistent with this study (more chimeric results mean more influence of 
visual cues). However, a study by Martin (34) showed no differences in illusory responses 
between individuals with schizophrenia and matched controls. The sound induced flash 
illusion in the study by Hourani (1) also investigating auditory and visual modalities did not 
show any significant differences in illusion strength between DEX and placebo days. The 
conflicting results makes it thus difficult to draw any conclusions about temporal windows 
and illusion strength in the visual and auditory modalities.  
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6.5 Phantom word illusion  
One subpopulation of participants had shorter latency and greater count with DEX 
compared to placebo, as hypothesised by Lloyd (28) (figure 15, component 2). That is, with 
higher DEX-levels in saliva, individuals had shorter time to perceive a new word and 
perceived more new words compared to placebo. Component 1 in the same PCA accounting 
for most of the variance, however, showed the opposite relationships. That is, with increasing 
DEX concentration in saliva, the greater latency and less new word perceived by participants 
while illusion strength actually increased with DEX. Next interesting predictor to look into 
would be rate of change of DEX-level in saliva. Taken together, the lack of power because of 
the limited amount of subjects in the phantom word illusion test makes it difficult to draw any 
conclusions about the relationships between DEX-levels in saliva and illusory outcome. 
Further studies with greater sample sizes are necessary. 
 
6.6 General limitations 
One explanation to why DEX-levels in saliva correlated poorly with illusion strength could 
be explained by subpopulations receiving placebo on the first day. The differences in outcome 
on illusory effects between DEX and placebo on most of the results are smaller when placebo 
comes first than when it comes from the second testing day. We ascribe this to the novelty of 
the testing situation and the initial anxiety regarding participating in a drug study elevating 
DA levels on the first day of testing. Another explanation could be due to that some 
individuals are resistant to the illusions (do not get the illusion any of the days). Another 
aspect is that DEX-levels in saliva may not be a valid representation of brain levels of DEX. 
For example, individual differences in saliva pH can produce between-subjects’ variability in 
saliva levels without corresponding to variability in brain levels.  
One explanation to the limited difference in illusion strength between DEX and placebo 
days (only significant at certain conditions in VIFI, not significant in SIFI and 3-FI) could be 
because the dose of DEX is too low. In future studies it would be interesting to administer 
different doses which would also make dose-response relationships across individuals more 
reliable (as differences in DEX concentrations across individuals would be greater). To 
further enhance the psychosis-state, another suggested improvement for future studies would 
be to have the participants sleep deprived in addition to DEX administration. Sleep 
deprivation has been shown to increase psychotic-like symptoms in otherwise healthy 
individuals (35). 
 
 
 
 31 
Another explanation to why illusion strength was not greater, or why there was no widened 
temporal binding window with DEX, could be because of acute dopamine adaptation in the 
brain. This is for example obvious with the subjective effects (peaking at 70 min), while 
levels of DEX in saliva continues to rise and remain high for a long time. The different 
physiological measures also vary differently in comparison to DEX levels in saliva. These 
findings do not only make it hard to draw conclusions about how well DEX levels in saliva 
mirror DA-levels in the brain, it also gives an indication that a potentially widened window 
with DEX might be an effect that is only present a short time, perhaps outside of the testing 
schedule (especially illusion tests carried out late in the day).  
As previously mentioned, euphoric subjective effects of DEX peaked at the first testing 
opportunity of the day set to 70 minutes post treatment. It would be interesting to have a 
measurement before this, suggesting a change of the time intervals of saliva collection, AMQ 
assessment and physiological measures to 50, 100, 150, 200 and 250. Alternatively, another 
control could just be added before 70 minutes (perhaps at 30) which might be more 
convenient when comparing results with previous studies having the present schedule.   
Correlations of DEX-levels in saliva and scores from illusion tests were based on values 
from the saliva sample closest in time to illusion test, rather than the actual time of the illusion 
test. Also, looking at the actual time of when saliva samples were taken, this varied a lot 
between individuals and also from the scheduled times (70, 130, 180, 225 min post treatment) 
making interpretations of the correlations more uncertain.   
Small sample size is another limitation of this study, particularly in the studies involving 
the McGurk- and Phantom word illusions where a lot of data had to be drawn back because of 
failure of the illusion test setup.  
 
6.7 Limitations of the detection and quantification methods 
Regarding the extraction- and HPLC-methods, MDMA as an internal standard was not 
optimal. Firstly, MDMA and DEX share similar chemical properties which requires the use of 
gradient analysis, giving poor baselines which in turn makes integration of peaks less reliable. 
Secondly, preparing the calibration curve by spiking volunteers’ saliva with DEX and 
MDMA, there was, repeatedly, an interfering peak around the time of MDMA further adding 
to the uncertainty of integrating the MDMA peak. 
Furthermore, integration of peaks in saliva samples from participants’ testing days was yet 
harder to integrate, these samples containing more interfering peaks both at the retention time 
of DEX and MDMA. In some cases, the shoulder of an interfering peak was too close to the 
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peak of interest that the EmpowerÒ software did not allow for integration. In these cases, a 
print-screen of the chromatogram was printed on paper, the peaks of MDMA and DEX cut 
out with scissors and weighted. Ratios were obtained from the difference in weight. 
Inconsistencies in the method of obtaining ratios further increase the uncertainty of the 
method.  
The identification method of standards being run before each new HPLC-session also had 
its limitations. The retention times of DEX and MDMA were sometimes in between two 
peaks in the chromatogram, making it difficult to identify the right peak. The interfering 
peaks were most likely metabolites from DEX.  
It might be possible to optimise the HPLC-method in future studies, preferably with an 
internal standard less like DEX in chemical properties. Although making separation greater 
between DEX, its metabolites and the internal standard would most likely require a gradient 
analysis (previously criticised in this paper) and extensive pilot testing. To improve the 
identification method, standards should at least be run not only in the beginning of an HPLC-
session but between one participant’s saliva samples and the next.  
7. CONCLUSION 
DEX-levels in saliva showed in our study to be an unreliable predictor of performance on 
illusion tests. It further raises the question to what extent DEX levels in saliva mirrors actual 
dopamine levels in the brain. Because of a number of limitations of the study design and small 
sample size our results are, however, inadequate to draw any well-founded conclusions. The 
study should be viewed as a pilot study where further studies within the field are necessary.  
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8. POPULÄRVETENSKAPLIG SAMMANFATTNING 
Schizofreni är en psykiatrisk sjukdom med många olika symptom, bland annat 
hallucinationer. Hallucinationer är sensoriska upplevelser som saknar sensorisk stimuli från 
verkligheten, t ex att höra en röst utan att någon pratar. I dagsläget är det fortfarande oklart 
exakt vilka mekanismer som ligger bakom schizofreni, men en övertygande faktor är för höga 
nivåer av signalsubstansen ”dopamin” i hjärnan. Ett sätt att studera schizofreni är att ge friska 
individer dexamfetamin, en substans som ökar dopamin i hjärnan och därmed härmar 
schizophreni-tillståndet. I två olika studier fann man att individer som tagit dexamfetamin 
upplevde illusioner starkare än individer som tagit sockerpiller. En illusion är en felaktig 
upplevelse av verkligheten, men som till skillnad från en hallucination, stimulerats av yttre 
sensoriskt stimuli. T ex en skugga från ett träd uppfattas som en människa. Syftet med denna 
studie var att undersöka eventuella samband mellan illusionsstyrka och nivå av dexamfetamin 
i saliv. Det vill säga, har individer med högre koncentration dexamfetamin i saliv starkare 
illusioner jämfört med en individ med lägre koncentration?  
Det fösta steget i denna studie var att etablera en metod för att mäta koncentrationen av 
dexamfetamin i saliv. Därefter gjordes jämförelser med hur dexamfetamin-koncentration i 
saliv varierade över dagen med subjektiva mått av upplevelsen av dexamfetamin, dvs eufori- 
och ångestkänslor.  
Resultaten visade att koncentrationen av dexamfetamin i saliv i snitt var som högst 130 
minuter efter administration av dexamfetamin och de subjektiva upplevelserna av drogen som 
störst 70 minuter efter administration. Eufori dominerade den subjektiva erfarenheten jämfört 
med ångest. Illusionsstyrka korrelerade med koncentration av dexamfetamin i saliv i vissa 
illusioner, medan en sådan korrelation inte förekom i andra illusioner. Det vill säga, höga 
koncentrationer av dexamfetamin i saliv behöver inte nödvändigtvis innebära starkare 
illusion.  
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APPENDICES 
Appendix 1 - Inclusion and Exclusion Criteria   
Be >17 and <60 years of age  
If female, not be pregnant, and be using contraceptives if sexually active and fertile. This is to 
exclude you from the experiment in case you have recently become pregnant but do not yet 
know of it.  
 
Exclusion criterias:  
• Heart or severe blood vessel disease, 
• High blood pressure 
• Glaucoma 
• Hyperthyroidism (overactive thyroid) 
• Tics (muscle twitching usually in the face or shoulders) 
• Sensitivity to dexamphetamine or sympathomimetic amines 
• Any degenerative disease of the nervous system 
• Epilepsy, or other neurological disorder, including head injury 
• Tourette's syndrome or you have a family history of this disorder 
• A psychiatric or psychological problem for which you are receiving treatment 
(schizophrenia, depression, anxiety, etc) 
• A serious medical problem for which you are receiving treatment (cardiovascular 
disorders, respiratory disorders, etc) 
• Had or are currently receiving treatment for substance abuse 
• A family history of schizophrenia in your first-degree relatives (parents, children or 
siblings) 
• Previously experienced hypersensitivity to dexamphetamine 
• Used any drug including alcohol or any illicit drug within 24 hours of each testing 
session 
• Used caffeine on the day of each testing session 
• Current prescription medication that you are taking other than oral contraceptives or 
acne medication  
• Used over-the-counter medication in the 48 hours before each testing session (see the 
last page of this information sheet for a list of medications) 
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Below is a list of over-the-counter medications that cannot be used in the 48 hours before 
each testing session:  
• Antihistamines,  
• Hayfever tablets (e.g. Sudafed),  
• Cough syrups,  
• Cold and flu tablets,  
• Codeine-containing medications,  
• Anti-nausea medications,  
• Sedatives,  
• Herbal supplements, particularly St John’s Wort.  
 
 
  
 
 
 39 
Appendix 2 – Schedule of testing days 
	
Time Minutes after 
treatment 
Task Duration (minutes) 
9:40 0 Saliva #1 5 
9:45 0 Treatment 60 
10:45 60 3FI 10 
10:55 70 Saliva #2 5 
11:00 75 Phantom 30 
11:30 105 Questionnaires: 
SAPS, BPRS, MIS  
10 
11:40 115 VIFI 15 
11:55 130 Saliva #3 5 
12:00 135 Lunch 30 
12:30 165 SIFI 15 
12:45 180 Saliva #4 5 
12:50 185 MHI 40 
13:30 225 Saliva #5 5 
13:35 230 TFI 10 
13:45 240 McGurk 10 
14:00 255 Home 5 
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Appendix 3 - Extraction Protocol 
	
Instructions C 
Thaw saliva samples and keep on ice.  
Pre-weigh 15 ml centrifuge tubes (blue screw cap). Write down the weight.  
Pipette approximately 1 ml of saliva into the centrifuge tube.  
Weigh tube + saliva and record the new weight.  
Add 100 µL of internal standard: 3000 ng/ml of MDMA in phosphate buffer, pH 2.8 
to each saliva sample. If calibration curve add 100 µl of the DEX-concentration. 
 
Add 0,1 ml of NaOH in order to make DEX and MDMA less soluble in the saliva.  
Add 10 ml of hexane/1%isoamyl alcohol to the alkalinized saliva.  
Shake vigorously for 5 minutes. An emulsion layer may form.  
Centrifuge at 1800 g for 5 minutes at 4°C.  
Using a 0,45 µm PVDF filter attached to a syringe, filter the organic phase (the 
supernatant phase) into a new 10 ml centrifuge tube (yellow cap). 
 
Filter 0,05M HCl with 0,45 PVDF microfilter.  
Add 150 µl of the filtered 0,05M HCl to the filtered organic phase.  
The HCl back-extracts DEX and MDMA into the aqueous layer. 
 
Shake tube vigorously for 5 minutes and centrifuge at 1800 g for 5 minutes at 4°C.  
The big part of the hexane-layer is then aspirated with a vacuum line.  
The remaining hexane is finally removed in a centrifugal evaporator SpeedVac at 
medium heat for 15-30 min (sc100, Savant with a pump vp 190 two solve). 
 
Pipette 150 µl of the HCl into the HPLC-veil.   
Set the HPLC system to inject duplicates of 30 µl volumes of each sample.   
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Appendix 4 - Phosphate buffer 
The phosphate buffer was prepared: 
1. 3.12 g of sodium dihydrogenphosphate dehydrate (M=156.01) was introduced in 1 litre of 
filtered water.  
2. 0.68 ml of phosphoric acid solution (85%) was then added to the solution. 
3. The pH was adjusted with acid until pH=2.8. 
 
